Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial f…
Biotechnology
US, Redwood City [HQ]
Strategy & Leadership
Mergers & Acquisitions Beta
M&A Details · Industry · Urgent
M&A Deals · Breakdown
Revolution Medicines, Inc. has no acquisition track records yet.
M&A Deals · History
Revolution Medicines, Inc. has no acquisition track records yet.
M&A Deals · Within Industry
No current deals within Biotechnology Industry.
M&A Deals · Latest
Act, dont react; Track the most urgent M&A deals across all industries
Details
Details
Details
?
Equity
Agg. Maximum Price
$4,221.65
?
Details
Details
United Bankshares, Inc.
Equity
Agg. Maximum Price
$206,633,909.86
?
Details
Details
Details
Icahn Enterprises L.P.
Debt
Agg. Maximum Price
$700,000,000.00
?
Details
Details
Corebridge Financial, Inc.
Debt
Agg. Maximum Price
$500,000,000.00